20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) operates in the BIOTECHNOLOGY industry and is headquartered in San Mateo, United States with about 16 employees. Its market capitalization is roughly $706 million. In the fiscal year ended 2025-12-31, SGMT reported $0M in revenue and ($51M) in net income.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $2M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | $2M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | 100.0% | — | — | — | — |
| Operating Income (EBIT) | ($53M) | ($57M) | ($54M) | ($31M) | ($31M) | ($24M) | ($11M) | ($14M) |
| Operating Margin % | — | — | — | -1537.0% | — | — | — | — |
| Net Income | ($47M) | ($51M) | ($46M) | ($28M) | ($30M) | ($24M) | ($11M) | ($14M) |
| Net Margin % | — | — | — | -1393.8% | — | — | — | — |
| EBITDA | ($50M) | ($51M) | ($46M) | ($28M) | ($31M) | ($24M) | ($11M) | ($14M) |
| Earnings Per Share (EPS) | $-1.28 | $-1.58 | $-1.45 | $-1.53 | $-1.38 | $-1.10 | $-0.51 | $-0.64 |
| Shares Outstanding (M) | 53M | 32M | 31M | 18M | 22M | 22M | 22M | 22M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($16M) | ($12M) | ($11M) | ($14M) | ($12M) | ($20M) | ($18M) | ($17M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($14M) | ($11M) | ($10M) | ($13M) | ($10M) | ($18M) | ($16M) | ($15M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($14M) | ($11M) | ($12M) | ($13M) | ($10M) | ($18M) | ($16M) | ($15M) |
| Earnings Per Share (EPS) | $-0.26 | $-0.33 | $-0.29 | $-0.40 | $-0.32 | $-0.56 | $-0.50 | $-0.45 |
| Shares Outstanding (M) | 53M | 33M | 33M | 32M | 32M | 32M | 32M | 32M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($41M) | ($46M) | ($42M) | ($24M) | ($24M) | ($22M) | ($10M) | ($11M) |
| Free Cash Flow (FCF) | ($41M) | ($46M) | ($42M) | ($24M) | ($24M) | ($22M) | ($10M) | ($11M) |
| FCF Margin % | — | — | — | -1188.3% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($11M) | ($9M) | ($12M) | ($10M) | ($9M) | ($15M) | ($11M) | ($20M) |
| Free Cash Flow (FCF) | ($11M) | ($9M) | ($12M) | ($10M) | ($9M) | ($15M) | ($11M) | ($20M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $263M | $116M | $160M | $97M | $33M | $59M | $69M | $11M |
| Cash & Cash Equivalents | $166M | $35M | $76M | $75M | $0M | $57M | $69M | $10M |
| Total Liabilities | $7M | $5M | $4M | $6M | $220M | $217M | $205M | $136M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $256M | $111M | $156M | $91M | ($187M) | ($158M) | ($136M) | ($125M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SGMT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms